Edgestream Partners’s Myriad Genetics MYGN Stock Holding History

Edgestream Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-55,842	Closed	-$1.53M	–	1011
2024 Q3	$1.53M	Buy	+55,842	New	+$1.51M	0.07%	473
2023 Q4	–	Sell	-39,855	Closed	-$639K	–	982
2023 Q3	$639K	Buy	39,855 +9,763	+32%	+$186K	0.05%	530
2023 Q2	$698K	Buy	+30,092	New	+$657K	0.06%	454
2022 Q3	–	Sell	-98,342	Closed	-$1.79M	–	563
2022 Q2	$1.79M	Buy	98,342 +63,233	+180%	+$1.31M	0.14%	226
2022 Q1	$885K	Sell	35,109 -17,937	-34%	-$459K	0.07%	345
2021 Q4	$1.46M	Sell	53,046 -11,817	-18%	-$342K	0.09%	267
2021 Q3	$2.09M	Sell	64,863 -93,992	-59%	-$3.12M	0.13%	231
2021 Q2	$4.86M	Buy	+158,855	New	+$4.59M	0.29%	125

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Edgestream Partners's MYGN Position: Q4 2024 in Review

Edgestream Partners sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 55,842 shares — an estimated $1.53M sold.

Edgestream Partners first reported a position in MYGN in Q2 2021 and held it in 8 quarters. The position peaked at $4.86M in Q2 2021. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

Edgestream Partners reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
Edgestream Partners sold 55,842 Myriad Genetics shares in Q4 2024, an estimated $1.53M.
Edgestream Partners first reported a position in Myriad Genetics in Q2 2021 and held it in 8 quarters.
Edgestream Partners's Myriad Genetics position peaked at $4.86M in Q2 2021.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Edgestream Partners's 13F filing for Q4 2024, filed 7 Feb 2025.